Stock listing
NASDAQ:CTNM Contineum Therapeutics, Inc. Stock
Home listing (NASDAQ) of Contineum Therapeutics, Inc.
Follow Contineum Therapeutics, Inc. into a list and get an email when it puts out news.
Share price · NASDAQ:CTNM
$8.68 USD -0.56 (-6.1%)
Close on Nov 20, 2026
- Day range
- $8.50 – $9.09 USDNov 20, 2026
- Volume
- 369,211 sharesNov 20, 2026
- Market cap
- $286.1M USDAt the close on Nov 20, 2026 · price × 32.96M shares outstanding
- 52-week range
- $6.73 – $17.79 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $8.47M USDMedian day 525,811 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:CTNM · Home | $8.68 USD | -0.56 (-6.1%) | 369,211 | $8.87 | $9.09 | $8.50 | $9.24 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:CTNM · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $8.68 | -0.56 | -6.1% | $8.87 | $9.09 | $8.50 | 369,211 | |
| $9.24 | -0.31 | -3.2% | $9.85 | $9.85 | $9.23 | 204,006 | |
| $9.55 | -0.12 | -1.2% | $9.58 | $9.685 | $9.33 | 294,107 | |
| $9.67 | -0.19 | -1.9% | $9.67 | $9.93 | $9.46 | 348,145 | |
| $9.86 | +0.08 | +0.8% | $9.775 | $10.14 | $9.38 | 265,893 | |
| $9.78 | -0.99 | -9.2% | $10.71 | $10.89 | $9.74 | 315,426 | |
| $10.77 | +0.21 | +2.0% | $10.68 | $10.91 | $10.57 | 287,645 | |
| $10.56 | +0.26 | +2.5% | $10.24 | $10.61 | $10.01 | 249,721 | |
| $10.30 | +0.78 | +8.2% | $9.74 | $10.50 | $9.32 | 264,636 | |
| $9.52 | +0.71 | +8.1% | $8.96 | $9.79 | $8.59 | 343,535 | |
| $8.81 | -0.98 | -10.0% | $9.59 | $9.84 | $8.65 | 584,009 | |
| $9.79 | +0.10 | +1.0% | $10.00 | $10.32 | $9.56 | 804,447 | |
| $9.69 | +0.13 | +1.4% | $9.57 | $9.935 | $9.54 | 525,811 | |
| $9.56 | +0.17 | +1.8% | $9.46 | $9.64 | $9.13 | 369,006 | |
| $9.39 | +0.06 | +0.6% | $9.14 | $9.58 | $8.94 | 458,621 | |
| $9.33 | +0.18 | +2.0% | $9.13 | $9.865 | $9.13 | 566,921 | |
| $9.15 | +0.16 | +1.8% | $8.92 | $9.34 | $8.59 | 570,475 | |
| $8.99 | +0.85 | +10.4% | $8.18 | $9.12 | $8.02 | 642,897 | |
| $8.14 | -0.17 | -2.0% | $8.25 | $8.59 | $8.02 | 402,682 | |
| $8.31 | -0.085 | -1.0% | $8.24 | $8.43 | $8.01 | 428,769 | |
| $8.395 | +0.045 | +0.5% | $8.32 | $8.75 | $8.12 | 498,754 | |
| $8.35 | -0.11 | -1.3% | $8.49 | $8.79 | $8.15 | 1,116,729 | |
| $8.46 | +1.02 | +13.7% | $7.38 | $8.70 | $7.145 | 2,200,902 | |
| $7.44 | +0.36 | +5.1% | $7.01 | $7.45 | $6.725 | 1,796,473 | |
| $7.08 | -0.82 | -10.4% | $7.87 | $7.87 | $6.95 | 1,108,100 | |
| $7.90 | -0.24 | -2.9% | $8.25 | $8.56 | $7.72 | 1,018,200 | |
| $8.14 | -0.28 | -3.3% | $8.21 | $8.796 | $7.96 | 1,014,500 | |
| $8.42 | -0.145 | -1.7% | $8.56 | $8.94 | $8.095 | 2,649,100 | |
| $8.565 | -4.815 | -36.0% | $9.90 | $11.54 | $8.425 | 8,463,200 | |
| $13.38 | +0.20 | +1.5% | $13.17 | $13.86 | $12.94 | 885,600 | |
| $13.18 | +0.45 | +3.5% | $12.55 | $13.29 | $12.39 | 1,178,300 | |
| $12.73 | +0.08 | +0.6% | $12.42 | $13.01 | $12.31 | 707,700 | |
| $12.65 | -0.07 | -0.6% | $12.88 | $12.88 | $12.17 | 761,900 | |
| $12.72 | -0.40 | -3.0% | $13.14 | $13.30 | $12.41 | 508,400 | |
| $13.12 | +0.13 | +1.0% | $13.15 | $13.24 | $12.59 | 794,300 | |
| $12.99 | -0.43 | -3.2% | $13.30 | $13.50 | $12.62 | 774,000 | |
| $13.42 | +1.92 | +16.7% | $11.59 | $13.55 | $11.59 | 1,597,800 | |
| $11.50 | -1.23 | -9.7% | $12.83 | $13.09 | $10.84 | 854,900 | |
| $12.73 | +0.17 | +1.4% | $12.38 | $13.36 | $11.95 | 534,100 | |
| $12.56 | +0.07 | +0.6% | $12.57 | $12.88 | $12.10 | 404,900 | |
| $12.49 | -0.02 | -0.2% | $12.49 | $12.74 | $11.40 | 632,200 | |
| $12.51 | -0.89 | -6.6% | $13.33 | $13.33 | $12.44 | 550,300 | |
| $13.40 | -0.15 | -1.1% | $13.74 | $14.00 | $13.19 | 770,300 | |
| $13.55 | +0.02 | +0.1% | $13.69 | $13.89 | $13.44 | 638,500 | |
| $13.53 | +0.32 | +2.4% | $13.23 | $13.89 | $13.15 | 2,139,400 | |
| $13.21 | -0.55 | -4.0% | $14.07 | $14.40 | $12.86 | 580,100 | |
| $13.76 | -0.06 | -0.4% | $13.97 | $14.60 | $13.70 | 786,000 | |
| $13.82 | -1.00 | -6.7% | $13.76 | $14.18 | $13.08 | 704,600 | |
| $14.82 | 0.00 | 0.0% | $14.89 | $15.51 | $14.74 | 607,600 | |
| $14.82 | +0.16 | +1.1% | $14.94 | $15.24 | $14.62 | 165,100 | |
| $14.66 | -0.48 | -3.2% | $14.97 | $15.22 | $14.61 | 203,300 | |
| $15.14 | -0.80 | -5.0% | $15.81 | $16.06 | $15.09 | 388,800 | |
| $15.94 | -0.76 | -4.6% | $16.59 | $16.95 | $15.88 | 316,200 | |
| $16.70 | -0.87 | -5.0% | $17.38 | $17.71 | $16.50 | 346,200 | |
| $17.57 | +0.33 | +1.9% | $17.39 | $17.79 | $17.03 | 320,800 | |
| $17.24 | +0.69 | +4.2% | $16.64 | $17.31 | $16.59 | 298,600 | |
| $16.55 | +0.31 | +1.9% | $16.07 | $16.77 | $15.81 | 212,100 | |
| $16.24 | -0.81 | -4.8% | $16.90 | $17.07 | $15.97 | 360,200 | |
| $17.05 | -0.20 | -1.2% | $17.06 | $17.40 | $16.93 | 477,800 | |
| $17.25 | +0.23 | +1.4% | $16.95 | $17.50 | $16.68 | 432,400 | |
| $17.02 | -0.03 | -0.2% | $16.98 | $17.32 | $16.66 | 387,900 | |
| $17.05 | +0.42 | +2.5% | $16.80 | $17.51 | $16.47 | 724,700 | |
| $16.63 | -0.56 | -3.3% | $17.00 | $17.24 | $16.23 | 261,100 | |
| $17.19 | +1.17 | +7.3% | $16.18 | $17.35 | $15.88 | 353,900 | |
| $16.02 | 0.00 | 0.0% | $15.80 | $16.29 | $15.68 | 321,300 |
- Ticker
- NASDAQ:CTNM
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Currency
- USD
What changed lately
Latest news release · Nov 9, 2026
Qureight’s Fibrosis Imaging Biomarker Selected by Contineum Therapeutics as a Secondary Endpoint in Phase 2 PROPEL-IPF Clinical Trial
Latest deck · July 2026
Investor Presentation (July 2026)
Investor deck · 32 slides
Latest news
Qureight’s Fibrosis Imaging Biomarker Selected by Contineum Therapeutics as a Secondary Endpoint in Phase 2 PROPEL-IPF Clinical Trial
Nov 9, 2026
Closed $10.30 (+8.2%) on Nov 9, 2026
Contineum Therapeutics Reports Third-Quarter 2026 Financial Results
Nov 3, 2026
Closed $9.79 (+1.0%) on Nov 4, 2026
Contineum Therapeutics to Present at the Stifel 2026 Healthcare Conference
Oct 29, 2026
Closed $9.39 (+0.6%) on Oct 30, 2026
Contineum Therapeutics Reports Phase 2 Results for JNJ-5120/PIPE-307 for the Treatment of Major Depressive Disorder
Sep 14, 2026
Closed $13.82 (-6.7%) on Sep 15, 2026
Contineum Therapeutics to Present at the 2026 Morgan Stanley Global Healthcare Conference
Aug 25, 2026
Closed $17.02 (-0.2%) on Aug 26, 2026
Contineum Therapeutics Reports Second-Quarter 2026 Financial Results; Affirms Key Clinical Development Milestones
Jul 30, 2026
Closed $15.49 (-1.7%) on Jul 31, 2026
Contineum Therapeutics to Present at the 2026 Goldman Sachs Global Healthcare Conference
Jun 1, 2026
Closed $12.38 (-5.4%) on Jun 2, 2026
Contineum Therapeutics to Present at the 2026 RBC Capital Markets Global Healthcare Conference
May 12, 2026
Closed $14.15 (+3.6%) on May 13, 2026
Contineum Therapeutics Announces Two Upcoming Posters at the American Thoracic Society (ATS) 2026 International Conference
May 11, 2026
Closed $13.66 (+0.1%) on May 12, 2026
Contineum Therapeutics Reports First-Quarter 2026 Financial Results; Affirms Key Clinical Development Milestones
May 5, 2026
Closed $14.39 (+1.7%) on May 5, 2026
Contineum Therapeutics, Inc. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 18 in the last 12 months · 46 in all · newest Nov 9, 2026 · oldest 2024
- Decks
- 3 decks · latest July 2026
Where Contineum Therapeutics, Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:CTNM · Home listing · This page | NASDAQ | United States | USD |
| BOATS:CTNM | BOATS | United States | USD |
Valuation
Price/book 1.2× against a median of 3.3×: 2nd lowest of 8 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- $47.86M USD
- P/E
- Loss
- EV/sales
- No revenue
- EV/EBITDA
- Negative EBITDA
- Price/book
- 1.2×
- Gross margin
- No revenue
- Operating margin
- No revenue
- Net margin
- No revenue
- Debt to equity
- 0.0×
- Beta vs S&P 500
- 1.53
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Contineum Therapeutics, Inc. · NASDAQ:CTNM | US$286.1M | US$47.86M | n/a | n/a | n/a | 1.2× | n/a | 0.0× | 1.53 |
| TRex Bio, Inc. · NASDAQ:TRXB | US$283.1M | US$205.0M | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Greenwich LifeSciences, Inc. · NASDAQ:GLSI | US$282.6M | US$276.7M | n/a | n/a | n/a | n/a | n/a | n/a | 2.80 |
| Precision BioSciences, Inc. · NASDAQ:DTIL | US$282.5M | US$228.3M | n/a | 5.1× | n/a | 5.5× | −85.6% | 0.5× | 0.30 |
| AP Biosciences, Inc. · TPEX:6945 | US$282.3M | US$215.7M | n/a | n/a | n/a | 4.0× | n/a | 0.0× | n/a |
| Fulcrum Therapeutics, Inc. · NASDAQ:FULC | US$281.8M | −US$17.87M | n/a | n/a | n/a | 0.9× | n/a | 0.0× | 0.42 |
| Circio Holding ASA · OSL:CRNA | US$281.1M | US$225.8M | n/a | n/a | n/a | 5.3× | n/a | 0.0× | n/a |
| Relmada Therapeutics, Inc. · NASDAQ:RLMD | US$279.5M | US$77.42M | n/a | n/a | n/a | 1.4× | n/a | 0.0× | 1.57 |
| Benitec Biopharma Inc. · NASDAQ:BNTC | US$276.1M | US$99.78M | n/a | n/a | n/a | 1.6× | n/a | 0.0× | 1.46 |
| Galectin Therapeutics Inc. · NASDAQ:GALT | US$271.4M | US$293.0M | n/a | n/a | n/a | n/a | n/a | n/a | 1.20 |
| Vicore Pharma Holding AB · OMXSTO:VICO | US$271.2M | US$182.6M | n/a | 467× | n/a | 3.3× | n/a | 0.0× | n/a |
| Median of the others | US$281.5M | US$210.3M | 236× | 3.3× | −85.6% | 0.0× | 1.33 |
Forecasts
5 strong buy · 1 buy · 2 hold · Analysts' consensus from EODHD, read Nov 19, 2026. Not 6ix's view and not investment advice.
- Price target
- 21.43 USD · Analysts' mean
- EPS, year to Dec 2026
- -1.78 · 7 analysts
Team and board
Officers
| Officer | Role |
|---|---|
| Carmine Stengone | President and Chief Executive Officer |
| Troy Ignelzi | Chief Financial Officer, Rapport Therapeutics, Inc. |
| Diego Miralles | President and Head of Research and Development, Artiva Biotherapeutics, Inc. |
| Evert Schimmelpennink | President, LENZ Therapeutics |
| Contineum Therapeutics | Senior Director, Investor Relations & Corporate Communications |
| Todd Brady | Director of Finance and Investments, Brace Pharma Capital |
Board
| Director | Role |
|---|---|
| Carmine Stengone | President and Chief Executive Officer |
| Diego Miralles | President and Head of Research and Development, Artiva Biotherapeutics, Inc. |
| Olivia Ware | Director |
| Sarah Boyce | Director |
| Troy Ignelzi | Chief Financial Officer, Rapport Therapeutics, Inc. |
Events
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Nov 3, 2026 · After close | +1.0% |
| Q2 2026 | Jul 30, 2026 · After close | −1.6% |
| Q1 2026 | May 5, 2026 · After close | +3.8% |
| Q4 2025 | Mar 5, 2026 | −6.6% |
| Q3 2025 | Oct 30, 2025 · After close | +4.5% |
| Q2 2025 | Aug 5, 2025 · After close | +5.5% |
| Q1 2025 | May 14, 2025 · After close | +2.6% |
| Q4 2024 | Mar 6, 2025 · After close | +5.1% |
| Q3 2024 | Nov 6, 2024 · After close | +7.6% |
| Q2 2024 | Aug 13, 2024 · After close | +6.2% |
All 12 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q1 2024 | May 16, 2024 · After close | +3.6% |
| Q4 2023 | Feb 28, 2024 |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (July 2026) | Investor deck | 32 slides | July 2026 |
| Technical Presentation (April 2026) | Technical | 14 slides | Apr 30, 2026 |
| Technical Presentation (September 2025) | Technical | 9 slides | Sep 18, 2025 |
Financings
| Raise | Date |
|---|---|
| Public offering of shares of Class A common stock Made bigger: about US$90M · US$12.25 a share · Goldman Sachs & Co. LLC +5 Dealers: Goldman Sachs & Co. LLC (co-lead), Leerink Partners (co-lead), Stifel (co-lead), RBC Capital Markets (co-lead), William Blair (co-lead), Jones | Dec 12, 2025 |
Open Financings · Read by 6ix AI from the company's releases
IPO
Priced at US$16.00 a share on Apr 4, 2024.
- Price
- US$16.00 a share
- Shares offered
- 6,875,000 shares of Class A common stock
- Offering size
- US$110 million
- Underwriters' option
- Up to 1,031,250 more shares
- Underwriters
- Goldman Sachs & Co. LLC, Morgan Stanley, Stifel, RBC Capital Markets · In the order on the cover
- Shares delivered
- On or about Apr 9, 2024
Steps
| Step | When |
|---|---|
| Draft sent to the SEC in confidence | Dec 13, 2023 |
| Filed publicly | Mar 15, 2024 |
| Amended once | Apr 1, 2024 |
| Shares registered with an exchange | Apr 2, 2024 |
| Declared effective by the SEC | Apr 4, 2024 |
| Final prospectus, with the price | Apr 8, 2024 |
Filings
| Filing | Filed |
|---|---|
| 424B4 · Prospectus | Apr 8, 2024 |
| EFFECT · Notice that a registration is effective | Apr 4, 2024 |
| CERT · Exchange's certificate of listing | Apr 4, 2024 |
| 8-A12B · Registration of shares for listing on an exchange | Apr 2, 2024 |
| CORRESP · Letter to the SEC | Apr 2, 2024 |
| CORRESP · Letter to the SEC | Apr 2, 2024 |
| S-1/A · Registration statement, amended | Apr 1, 2024 |
| CORRESP · Letter to the SEC | Mar 21, 2024 |
| CORRESP · Letter to the SEC | Mar 15, 2024 |
| S-1 · Registration statement | Mar 15, 2024 |
All 18 filings
| Filing | Filed |
|---|---|
| UPLOAD · Letter from the SEC | Feb 23, 2024 |
| DRSLTR · Letter to the SEC with a draft | Feb 15, 2024 |
| DRS/A · Draft registration statement, amended | Feb 15, 2024 |
| UPLOAD · Letter from the SEC | Feb 7, 2024 |
| DRSLTR · Letter to the SEC with a draft | Jan 29, 2024 |
| DRS/A · Draft registration statement, amended | Jan 29, 2024 |
| UPLOAD · Letter from the SEC | Jan 11, 2024 |
| DRS · Draft registration statement | Dec 13, 2023 |
Open IPO · From the cover of the final prospectus (424B4) filed Apr 8, 2024
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 50.0M | 0 | 0 |
| Cost of revenue | 323.0K | 258.0K | 195.0K | 329.0K | |
| Gross profit | -323.0K | -258.0K | 50.0M | -329.0K | |
| Research and development | 51.5M | 38.4M | 27.6M | 16.9M | 22.4M |
| Selling, general and administrative | 16.5M | 12.5M | 6.32M | 5.83M | 6.29M |
| Operating income | -68.1M | -50.9M | 16.1M | -22.7M | -28.6M |
| Depreciation and amortization | 323.0K | 258.0K | 195.0K | 329.0K | 325.0K |
| EBITDA | -67.7M | -50.6M | 16.3M | -22.4M | -28.3M |
| Interest expense | 0 | 208.0K | 388.0K | 332.0K | |
| Income before tax | -60.1M | -42.3M | 23.2M | -24.3M | -29.0M |
| Income tax | 0 | 0 | 450.0K | 241.0K | |
| Net income | -60.0M | -42.3M | 22.7M | -24.3M | -29.0M |
| Earnings per share, basic | -2.17 | -2.18 | 1.36 | -0.97 | -1.15 |
| Earnings per share, diluted | -2.17 | -2.18 | 0.08 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Cash and equivalents | 75.6M | 21.9M | 15.5M | 5.57M | 4.63M |
| Short-term investments | 187.3M | 182.8M | 109.7M | 41.7M | 64.4M |
| Current assets | 267.9M | 206.4M | 127.7M | 48.4M | 69.8M |
| Property, plant and equipment | 830.0K | 989.0K | 678.0K | ||
| Total assets | 276.6M | 212.8M | 130.4M | 50.6M | 70.5M |
| Accounts payable | 1.02M | 1.81M | 635.0K | 430.0K | 660.0K |
| Current liabilities | 9.74M | 9.97M | 5.48M | 7.55M | 3.67M |
| Long-term debt | 3.66M | ||||
| Total debt | 8.25M | 6.26M | 193.2M | 5.85M | 4.91M |
| Total liabilities | 15.7M | 14.8M | 5.70M | 11.4M | 8.93M |
| Shareholders' equity | 261.0M | 198.1M | -67.9M | 39.3M | 61.6M |
| Shares outstanding | 27.7M | 25.9M | 2.35M | 25.1M | 25.1M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Cash from operations | -55.3M | -32.8M | 19.3M | -20.1M | -26.3M |
| Capital spending | -231.0K | -514.0K | -414.0K | -118.0K | -168.0K |
| Free cash flow | -55.5M | -33.4M | 18.9M | -20.2M | -26.4M |
| Cash from investing | -3.71M | -69.7M | -65.6M | 22.3M | -65.0M |
| Cash from financing | 112.7M | 109.0M | 56.2M | -1.24M | 79.8M |
| Share buybacks | 0 | -28.0K | -4.00K | 0 | |
| Change in cash | 53.7M | 6.42M | 9.96M | 939.0K | -11.4M |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 16, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 16, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 6, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Nov 5, 2026 | Big-stake notice | SEC |
| 144 · Notice of proposed sale | Nov 4, 2026 | Other filings | SEC |
| 10-Q · Quarterly report | Nov 3, 2026 | Quarterly report | SEC |
| 8-K · Current report | Nov 3, 2026 | Results | SEC |
| SCHEDULE 13G · Big-stake notice | Oct 28, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Oct 28, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Oct 22, 2026 | Big-stake notice | SEC |
Show 200 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 144 · Notice of proposed sale | Oct 1, 2026 | Other filings | SEC |
| 8-K · Current report | Sep 14, 2026 | Current report | SEC |
| 4 · Change in ownership | Sep 8, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Sep 8, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Sep 1, 2026 | Other filings | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 14, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Aug 3, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Aug 3, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Aug 3, 2026 | Other filings | SEC |
| 10-Q · Quarterly report | Jul 30, 2026 | Quarterly report | SEC |
| 8-K · Current report | Jul 30, 2026 | Results | SEC |
| SCHEDULE 13G · Big-stake notice | Jul 27, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Jul 17, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Jul 13, 2026 | Current report | SEC |
| 4 · Change in ownership | Jul 10, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jul 8, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jul 8, 2026 | Other filings | SEC |
| 4 · Change in ownership | Jul 2, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jul 1, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jul 1, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jul 1, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Jun 30, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Jun 30, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Jun 30, 2026 | Other filings | SEC |
| 4 · Change in ownership | Jun 26, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 26, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 26, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 26, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 26, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 26, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 26, 2026 | Insider trade | SEC |
| 8-K · Current report | Jun 26, 2026 | Meeting outcome | SEC |
| 4 · Change in ownership | Jun 1, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jun 1, 2026 | Other filings | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 15, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | May 15, 2026 | Big-stake notice | SEC |
| 10-Q · Quarterly report | May 5, 2026 | Quarterly report | SEC |
| 8-K · Current report | May 5, 2026 | Results | SEC |
| 4 · Change in ownership | May 1, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | May 1, 2026 | Other filings | SEC |
| ARS · Annual report to shareholders | Apr 30, 2026 | Annual report | SEC |
| DEFA14A · Additional proxy material | Apr 30, 2026 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 30, 2026 | Meeting notice | SEC |
| 8-K · Current report | Apr 30, 2026 | Current report | SEC |
| SCHEDULE 13G · Big-stake notice | Apr 17, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Apr 6, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Apr 6, 2026 | Other filings | SEC |
| S-8 · Registration statement for employee plans | Mar 5, 2026 | Offer document | SEC |
| 424B5 · Prospectus | Mar 5, 2026 | Offer document | SEC |
| 10-K · Annual report | Mar 5, 2026 | Annual report | SEC |
| 8-K · Current report | Mar 5, 2026 | Results | SEC |
| 4 · Change in ownership | Mar 2, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 2, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 26, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 26, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 20, 2026 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 17, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Feb 17, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Feb 17, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Feb 13, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 13, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Feb 11, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Feb 11, 2026 | Other filings | SEC |
| 4 · Change in ownership | Feb 5, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Feb 3, 2026 | Other filings | SEC |
| 4 · Change in ownership | Jan 30, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 30, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 30, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 30, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 30, 2026 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Jan 29, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Jan 26, 2026 | Management or board change | SEC |
| 4 · Change in ownership | Jan 6, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jan 5, 2026 | Other filings | SEC |
| 4 · Change in ownership | Dec 30, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 30, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Dec 29, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Dec 23, 2025 | Other filings | SEC |
| 8-K · Current report | Dec 15, 2025 | Material contract | SEC |
| 424B5 · Prospectus | Dec 12, 2025 | Offer document | SEC |
| 424B5 · Prospectus | Dec 11, 2025 | Offer document | SEC |
| 8-K · Current report | Dec 11, 2025 | Current report | SEC |
| 8-K · Current report | Nov 20, 2025 | Current report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 4, 2025 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Oct 30, 2025 | Quarterly report | SEC |
| 8-K · Current report | Oct 30, 2025 | Results | SEC |
| 8-K · Current report | Sep 18, 2025 | Current report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 14, 2025 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Aug 5, 2025 | Quarterly report | SEC |
| 8-K · Current report | Aug 5, 2025 | Results | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 5, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Jul 25, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Jun 26, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 26, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 26, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 26, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 26, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 26, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 26, 2025 | Insider trade | SEC |
| 8-K · Current report | Jun 26, 2025 | Meeting outcome | SEC |
| EFFECT · Notice that a registration is effective | May 27, 2025 | Other filings | SEC |
| CORRESP · Letter to the SEC | May 21, 2025 | Other filings | SEC |
| UPLOAD · Letter from the SEC | May 20, 2025 | Other filings | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 15, 2025 | Big-stake notice | SEC |
| S-8 · Registration statement for employee plans | May 14, 2025 | Offer document | SEC |
| 8-K · Current report | May 14, 2025 | Results | SEC |
| S-3 · Registration statement | May 14, 2025 | Offer document | SEC |
| 10-Q · Quarterly report | May 14, 2025 | Quarterly report | SEC |
| ARS · Annual report to shareholders | Apr 29, 2025 | Annual report | SEC |
| DEFA14A · Additional proxy material | Apr 29, 2025 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 29, 2025 | Meeting notice | SEC |
| 4 · Change in ownership | Apr 28, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Apr 28, 2025 | Insider trade | SEC |
| 8-K · Current report | Apr 28, 2025 | Current report | SEC |
| 4 · Change in ownership | Mar 17, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Mar 17, 2025 | Insider trade | SEC |
| 8-K · Current report | Mar 17, 2025 | Management or board change | SEC |
| S-8 · Registration statement for employee plans | Mar 6, 2025 | Offer document | SEC |
| 10-K · Annual report | Mar 6, 2025 | Annual report | SEC |
| 8-K · Current report | Mar 6, 2025 | Results | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 14, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 14, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Jan 31, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 31, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 31, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 31, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 31, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Nov 27, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Nov 20, 2024 | Insider trade | SEC |
| 144 · Notice of proposed sale | Nov 18, 2024 | Other filings | SEC |
| SC 13G · Big-stake notice | Nov 14, 2024 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Nov 6, 2024 | Quarterly report | SEC |
| 8-K · Current report | Nov 6, 2024 | Results | SEC |
| SCHEDULE 13G · Big-stake notice | Oct 31, 2024 | Big-stake notice | SEC |
| 4 · Change in ownership | Aug 14, 2024 | Insider trade | SEC |
| 10-Q · Quarterly report | Aug 14, 2024 | Quarterly report | SEC |
| 8-K/A · Current report, amended | Aug 14, 2024 | Results | SEC |
| 8-K · Current report | Aug 13, 2024 | Results | SEC |
| 4 · Change in ownership | Jun 24, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jun 24, 2024 | Insider trade | SEC |
| 8-K · Current report | Jun 24, 2024 | Management or board change | SEC |
| 4 · Change in ownership | Jun 3, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jun 3, 2024 | Insider trade | SEC |
| 8-K · Current report | May 31, 2024 | Management or board change | SEC |
| 4 · Change in ownership | May 29, 2024 | Insider trade | SEC |
| 4 · Change in ownership | May 29, 2024 | Insider trade | SEC |
| 4 · Change in ownership | May 29, 2024 | Insider trade | SEC |
| 4 · Change in ownership | May 29, 2024 | Insider trade | SEC |
| 4 · Change in ownership | May 29, 2024 | Insider trade | SEC |
| 4 · Change in ownership | May 29, 2024 | Insider trade | SEC |
| 4 · Change in ownership | May 29, 2024 | Insider trade | SEC |
| 4 · Change in ownership | May 29, 2024 | Insider trade | SEC |
| 4 · Change in ownership | May 29, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | May 20, 2024 | Insider trade | SEC |
| 4 · Change in ownership | May 20, 2024 | Insider trade | SEC |
| 8-K · Current report | May 20, 2024 | Management or board change | SEC |
| 10-Q · Quarterly report | May 16, 2024 | Quarterly report | SEC |
| 8-K · Current report | May 16, 2024 | Results | SEC |
| SC 13G · Big-stake notice | Apr 15, 2024 | Big-stake notice | SEC |
| SC 13G · Big-stake notice | Apr 15, 2024 | Big-stake notice | SEC |
| 4 · Change in ownership | Apr 11, 2024 | Insider trade | SEC |
| SC 13G · Big-stake notice | Apr 10, 2024 | Big-stake notice | SEC |
| 3 · Initial statement of ownership | Apr 10, 2024 | Insider trade | SEC |
| 8-K · Current report | Apr 9, 2024 | Current report | SEC |
| S-8 · Registration statement for employee plans | Apr 9, 2024 | Offer document | SEC |
| 424B4 · Prospectus | Apr 5, 2024 | Offer document | SEC |
| SEC STAFF LETTER | Apr 5, 2024 | Other filings | SEC |
| EFFECT · Notice that a registration is effective | Apr 5, 2024 | Other filings | SEC |
| 3 · Initial statement of ownership | Apr 4, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Apr 4, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Apr 4, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Apr 4, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Apr 4, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Apr 4, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Apr 4, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Apr 4, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Apr 4, 2024 | Insider trade | SEC |
| CERT · Exchange's certificate of listing | Apr 4, 2024 | Other filings | SEC |
| 8-A12B · Registration of shares for listing on an exchange | Apr 2, 2024 | Other filings | SEC |
| CORRESP · Letter to the SEC | Apr 2, 2024 | Other filings | SEC |
| CORRESP · Letter to the SEC | Apr 2, 2024 | Other filings | SEC |
| S-1/A · Registration statement, amended | Apr 1, 2024 | Offer document | SEC |
| CORRESP · Letter to the SEC | Mar 21, 2024 | Other filings | SEC |
| CORRESP · Letter to the SEC | Mar 15, 2024 | Other filings | SEC |
| S-1 · Registration statement | Mar 15, 2024 | Offer document | SEC |
| UPLOAD · Letter from the SEC | Feb 23, 2024 | Other filings | SEC |
| DRSLTR · Letter to the SEC with a draft | Feb 15, 2024 | Other filings | SEC |
| DRS/A · Draft registration statement, amended | Feb 15, 2024 | Offer document | SEC |
| UPLOAD · Letter from the SEC | Feb 7, 2024 | Other filings | SEC |
| SEC STAFF LETTER | Jan 30, 2024 | Other filings | SEC |
This page holds 200 of 204 filings. Open Filings
Cap table
Built by 6ix from Contineum Therapeutics, Inc.’s releases
- Common shares
- 32,958,632
- Fully diluted
- 32,958,632
Fully diluted
| Line | Shares |
|---|---|
| Common shares | 32,958,632 |
Share count over time
| Count | Shares |
|---|---|
| Nov 22, 2026 | 32,958,632 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Sarah Boyce Other companies: Atrium Therapeutics, Inc. (Chair · Since at least Feb 26, 2026); Avidity Biosciences, Inc (President and CEO, Director · Since at least Jun 11, 2020); OmniAb, Inc. (Director · Nov 1, 2022 – Jun 18, 2024 · Past); Berkeley Lights Inc (Director · Jul 16, 2020 – May 14, 2021 · Past); Ligand Pharmaceuticals Incorporated (Director · Oct 15, 2019 – Jun 10, 2022 · Past); Akcea Therapeutics Inc (President, Director · Apr 17, 2018 – Jul 15, 2019 · Past); Ionis Pharmaceuticals, Inc. (Chief Business Officer · Jan 1, 2015 – Jan 15, 2018 · Past) | Director · Since at least Jun 24, 2024 |
| Todd C. Brady Other companies: Aldeyra Therapeutics, Inc. (Chief Executive Officer, President & Director · Since at least May 1, 2014); Evoke Pharma Inc (Director · Since at least Sep 24, 2013); Avidity Biosciences, Inc (Director · Jun 11, 2020 – Jun 11, 2020 · Past); Cocrystal Pharma, Inc. (Director · Feb 1, 2019 – Feb 1, 2019 · Past); Spring Bank Pharmaceuticals Inc (Director · Jul 28, 2016 – Sep 30, 2020 · Past); Outlook Therapeutics, Inc. (Director · May 12, 2016 – Oct 26, 2017 · Past) | Director · Since at least Apr 4, 2024 |
| Troy Ignelzi Other companies: Harmony Biosciences Holdings, Inc. (Director · Since at least Apr 2, 2026); Rapport Therapeutics, Inc. (Chief Financial Officer · Since at least Jun 6, 2024); CinCor Pharma Inc (Director · Jan 6, 2022 – Feb 24, 2023 · Past); Karuna Therapeutics Inc (Chief Financial Officer · Jun 27, 2019 – Aug 22, 2023 · Past); Scpharmaceuticals Inc (Chief Financial Officer · Nov 16, 2017 – Jan 17, 2018 · Past) | Chief Financial Officer, Rapport Therapeutics, Inc. · Since at least May 20, 2024 |
| Evert Schimmelpennink Other companies: LENZ Therapeutics, Inc. (President, Chief Executive Officer, Secretary and Director · Since at least Mar 21, 2024); iBio, Inc. (Director · Since at least Jun 7, 2021); Pfenex Inc (See Remarks, Director · Aug 3, 2017 – Oct 1, 2020 · Past) | President, LENZ Therapeutics · Since at least Apr 4, 2024 |
| Gines Diego Miralles Other companies: Artiva Biotherapeutics, Inc. (President & Head of R&D · Since at least Jul 18, 2024); NeuBase Therapeutics Inc (Director · Jul 12, 2019 – Sep 9, 2020 · Past) | Director · Since at least Mar 14, 2025 |
| Lori Lyons-Williams Other companies: RAPT Therapeutics Inc (Director · Since at least Nov 9, 2021); Five Prime Therapeutics Inc (Director · Jun 23, 2019 – Apr 16, 2021 · Past) | Director · Since at least Apr 4, 2024 |
| Olivia Ware Other companies: Arcellx Inc (Director · Since at least May 16, 2022); Revance Therapeutics, Inc. (Director · Mar 6, 2021 – Feb 4, 2025 · Past) | Director · Since at least Apr 4, 2024 |
| Carmine Stengone Other companies: Kiora Pharmaceuticals, Inc. (Director · Since at least Aug 1, 2023) | President and Chief Executive Officer · Since at least Apr 4, 2024 |
| Diego Miralles Other companies: Artiva Biotherapeutics, Inc. (Director · Since May 19, 2026) | President and Head of Research and Development, Artiva Biotherapeutics, Inc. · Since at least Mar 17, 2025 |
| John Stephen Healy Other companies: Tyra Biosciences, Inc. (General Counsel and Secretary · Mar 1, 2022 – Mar 1, 2022 · Past) | General Counsel and Corp Sec · Since at least May 30, 2024 |
All 15 people
| Person | Seat |
|---|---|
| Contineum Therapeutics | Senior Director, Investor Relations & Corporate Communications · Since at least Sep 14, 2026 |
| Daniel S Lorrain | Chief Scientific Officer · Since at least Apr 4, 2024 |
| Peter T Slover | Chief Financial Officer · Since at least Apr 4, 2024 |
| Stephen L Huhn | CMO & Sr VP, Clinical Dev. · Apr 4, 2024 – Jan 31, 2025 · Past |
| Tim Watkins | CMO & Head of Development · Since at least Apr 28, 2025 |
Log in to ask 6ix AI your own questions about Contineum Therapeutics, Inc.